Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case. (September 2021)

• Record Type: Journal Article
• Authors: Connor, Bradley A; Couto-Rodriguez, Mara; Barrows, Joseph E; Gardner, Morgan; Rogova, Marina; O'Hara, Niamh B.; Nagy-Szakal, Dorottya
• Is Part Of: International journal of infectious diseases. Volume 110(2021)
• Page Start: 232
• Page End: 234
• Publication Date: 2021-09
• Subjects: B.1.617.2 -- Delta variant -- SARS-CoV-2 -- COVID-19 -- variant of concern -- breakthrough -- monoclonal antibody therapy -- bamlanivimab/etesevimab; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2021.07.029
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Vaccine breakthrough of father and son living in separate households Delta (B.1.617.2) variant vaccine breakthrough cases One case was severe enough to lead to hospitalization Despite high titer of anti-spike IgG, bamlanivimab/etesevimab provided resolution of symptoms ABSTRACT: We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.